Overzicht EULAR aanbevelingen

Table 1 The 2016 EULAR updated recommendations

The symbols (*, §, #) indicate different levels of evidence which are correspondingly provided together with voting results and levels of agreement in table 2.

1TNF-inhibitors: adalimumab, certolizumab pegol, etanercept, golimumb, infliximab boDMARDs or the respective EMA- approved/FDA-approved biosimilars.

2Abatacept, rituximab (as first bDMARD under special circumstances—see text), or tocilizumab or respective EMA- approved/FDA-approved biosimilars, as well as other IL-6 pathway inhibitors, sarilumab and/or sirukumab, once approved. 3Jak-inhibitors (where approved). boDMARDs, biological originator DMARDs; bsDMARD, biosimilar DMARDs; csDMARDs, conventional synthetic DMARDs; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; Jak, Janus kinase; MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.

 

Table 2 Evidence levels, voting results and agreement

The symbols (*, §, #) relate to the corresponding symbols in the recommendations (table 1), showing the respective LoE.

LoE, levels of evidence; n.a., not available; SoR, strength of recommendation.